Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    Day One Biopharmaceutical...

    NASDAQ: DAWN · Real-Time Price · USD
    6.80
    0.07 (1.04%)
    At close: Jul 03, 2025, 3:00 PM
    6.80
    0.00%
    After-hours: Jul 03, 2025, 04:20 PM EDT
    1.04%
    Bid 4.9
    Market Cap 689.26M
    Revenue (ttm) 161.92M
    Net Income (ttm) -69.08M
    EPS (ttm) -0.65
    PE Ratio (ttm) -10.46
    Forward PE -8.04
    Analyst Buy
    Ask 8.67
    Volume 445,456
    Avg. Volume (20D) 1,365,911
    Open 6.79
    Previous Close 6.73
    Day's Range 6.75 - 6.86
    52-Week Range 6.08 - 16.76
    Beta -1.30

    About DAWN

    undefined

    [Read more]
    Industry n/a
    Sector n/a
    IPO Date n/a
    Employees NaN
    Stock Exchange n/a
    Ticker Symbol DAWN
    Website n/a
    Full Company Profile

    Analyst Forecast

    According to 0 analyst ratings, the average rating for DAWN stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

    Stock Forecasts

    Why Price Moved

    Why Price Moved is a one-sentence explanation of why a stock is moving higher or down. By removing noise and collecting signals from news, press releases and SEC filings, we can pinpoint the trigger for price movements.
    4 months ago
    -16.5%
    Day One Biopharmaceuticals shares are trading lowe... Unlock content with Pro Subscription
    8 months ago
    +0.84%
    Day One Biopharmaceuticals shares are trading higher after the company reported better-than-expected Q3 financial results.
    news image

    1 month ago · seekingalpha.com

    Day One Biopharmaceuticals: Strong Ojemda Potential In Q2 And Solid Rationale For DAY-301

    DAWN reported modest Q1'25 sales growth vs Q4'24, and the reaction of the stock has unsurprisingly been muted. Upcoming Q2'25 earnings are pivotal: confirmation of accelerating growth could spark upsi...

    news image

    1 month ago · seekingalpha.com

    Day One Biopharmaceuticals, Inc. (DAWN) Q1 2025 Earnings Call Transcript

    Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN ) Q1 2025 Earnings Conference Call May 6, 2025 4:30 PM ET Company Participants Joey Perrone - Senior Vice President, Finance & Investor Relations Jeremy B...

    news image

    1 month ago · zacks.com

    Day One Biopharmaceuticals, Inc. (DAWN) Reports Q1 Loss, Tops Revenue Estimates

    Day One Biopharmaceuticals, Inc. (DAWN) came out with a quarterly loss of $0.35 per share versus the Zacks Consensus Estimate of a loss of $0.46. This compares to loss of $0.72 per share a year ago.

    news image

    2 months ago · https://www.marketscreener.com

    Investing in the $532B Oncology Boom: Key Stocks Shaping the Future of Cancer Treatment

    The global oncology drug market, valued at over $200 billion today, is on pace to reach $532 billion by 2031-a growth story driven not just by rising demand but by genuine innovation. After years of i...

    news image

    2 months ago · seekingalpha.com

    Day One Biopharmaceuticals Pullback Is A Potential Buying Opportunity

    Day One Biopharmaceuticals' Ojemda launched in Q2'24 and generated $57.2M in net product revenues in 2024. Despite reporting continued sales growth so far, DAWN's stock is near 52-week lows, perhaps i...

    Add to Watchlist